2022 / Italy
2022 / Italy
Biotechnology evolved by nature. EVE Biofactory will allow the sustainable and scalable production of extracellular vesicles for the creation of new therapeutics and new cosmetic formulations.
BIOTECH
SECTOR
Problem.
EV scalability.
EVs are considered the future of medicine, due to their ability to be loaded with, and deliver a wide range of molecules. However, right now their production (from human stem cells) is not scalable in a sustainable way and producers cannot meet the upcoming market demand.
Solution.
EVs evolved by nature.
EVE patented a novel method to produce and purify EVs starting from microalgae. This new production process is scalable, sustainable and more cost-effective with respect to the competitors. Allow the sustainable and scalable production of extracellular vesicles for the creation of new therapeutics and new cosmetic formulations.
The conception originated at the end of a challenging European research project under the Future and Emerging Technology program of the European Commission, known as VES4Us, which laid the groundwork for the exploitation of the strong scientific outcomes in the fields of cosmetics and pharmaceutics.
Meeting Day One was key in believing that scientists can also drive a company, exploiting the market potential of our scientific results. I met Paolo a couple years ago and it was love at first sight: I immediately realized that with his support, we could unleash our Nature’s nano treasures into the market..
1) Believe in science and its power in making a better world!
2) Take the risk and believe in your potential in being part of the market.
3) Be supported by Day One!
